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SCHEDULE OF PATENT INFRINGEMENT CHARACTERISTICS 
RE. CERBERUS COMPANY, MAENNEDORF, SWITZERLAND 
The Cerberus Company has patents issued .in most countries of the World 
covering ionization detec~ors and may be-initially presumed to interfer 
with our designs iri two specific areas: 
1) Internal voltage gradient in the ionization chamber is 
alleged to be _protected by their patent at voltage levels 
below five volts per centimeter. This patent we refer to 
as the' low voltage patent. This patent was issued in 
February 1966 and should expire in ·February 1983. 
2) The second patent of consequence concerns the Cerberus 
patents, again issued in most countries of the World, 
covering the use of an alpha emitter, precluding any 
measurable radiation beyond the distance of ten centi-
meters in ·free air.. ·The material used in ionization 
detectors manufactured by all companies, at least 99.9% 
of all product, is Americium 241, an alpha emitter · 
falling within the coverage of the claims of Cerberus. 
. . 
Statitrol Corporation, and to our knowledge no other company, has a 
license for use of both of the above patents extending into 1980, or 
the expiration of the radiation (alpha emitter) patent. 
The licensee for Cerberus in the U.S. and Canada is Pyrotronics, Inc., 
a New York Stock Exchange Company. · Pyrotronics Inc. ·is the first 
company to distribute ionization detectors for commercial use in this 
country, beginning about 1961. To our knowledge, Cerberus has not 
advised any U.S. company manufacturing detectors, whiGh might be infring-
ing on either of the above patents, that they may be violating or 
suggesting any form of royalty payment. In early 1975, the president 
of Pyro~ronics, Mr. Joe Johnson, advised Duane Pearsall that he had 
not been advised by Cerberus that they intended to pursue defense of 
their.patents. He did not understand why they had.not pursued this 
defense in the U.S. and indicated that per their license agreement with 
Cerberus, it was the prime responsibility of Cerberus to take this 
action. However, the agreement also provided that Baker Industries, 
or Pyrotronics~ could take such action on their own. 
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With the proliferation of products using both of these patented 
characteristics and have used them commercially. in large. quantities 
in the United States· since 1971, it appears as if they have inten-
tionally forfeited their rights. 
From the indepth research done by our attorneys and the attorneys for 
the Simplex Time Recorder Company in Germany and France, we believe 
there is sufficient prior art to seriously cl0ud the subject patents. 
We also have record of an early patent in the United States which did 
not issue in Europe, which would protect our position in the United 
States at a greater level than our defense in Europe. 
· Further, relative to the low voltage patent,· the first commercial detec-
· tor of Statitrol was sold in 1965, demonstrating prior ar~. 
In summary, it is the feeling of our management .that Statitrol is relatively 
well isolated from any potential action on the part·of Cerberus. Further, 
should such action be initiated on the part of Pyrotronics or Cerberus, 
Statitrol owns certain patents which we feel are being infringed by many 
manufacturers, including Pyrotronics, which will serve most adequately 
as "trading material". Although we assess the risks to Statitrol to be 
minimal, we also recognize that all areas involving patent rights are 
relatively unpredictable and always carry relative risks. 
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